Andy Studna, Senior Editor

In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.

Carie Pierce, SVP, global head of growth & business development, DIA touches on the various themes of the sessions which were held at the 2024 Global Annual Meeting including regulatory, technology, and harmonization.

Dovato regimen met its primary endpoint at 48 weeks for the treatment of HIV-1 in people who are virologically suppressed.

Pierce shares her greatest takeaways from this year's meeting in San Diego, CA.

Results of the studies, published in The Lancet, show delgocitinib cream met its primary and all secondary endpoints.

Study met its primary endpoint with statistically significant superior efficacy over 12 weeks of treatment compared to placebo.

The androgen receptor inhibitor significantly increased radiological progression-free survival in combination with androgen deprivation therapy compared to placebo.

Two-year data from duo of Phase III studies show potential for Susvimo as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Mixed methods study gathered responses from study investigators to identify barriers, solutions, and opportunities associated with continuing critical care randomized trials during the pandemic.

Newly released research report from Information Services Group suggests firms are moving away from traditional, centralized trials in favor of remote technologies.

deLaubenfels addresses key challenges seen by sponsors and highlights the value cough monitoring can provide.

Topline results from the 52-week open-label trial show the treatment was well tolerated with a safety profile consistent with standard-of-care.

The potential treatment for chemotherapy-induced peripheral neuropathy will be evaluated in a single ascending dose study.

Del Smith, PhD, co-founder & CEO of Acclinate highlights challenges sponsors may face in light of FDA releasing its Diversity Action Plan guidance.

Emerging data from Phase I first-in-human, dose-escalation study showed promising survival and progression-free survival rates.

Smith shares his initial thoughts on the guidance and what its impact will be on the industry moving forward.

Once-daily formulations of the oral GLP-1 receptor agonist resulted in encouraging pharmacokinetic data for several candidates, including one showing the most favorable profile.

In the fourth and final part of this video interview, Kristy Birchard, product owner, patient engagement, YPrime discusses the importance of designing products based on the experience of patients.

In part 3 of this video interview, Kristy Birchard, product owner, patient engagement, YPrime touches on the importance of utilizing patient-reported outcomes.

Under the new agreement, a Phase II study will commence to evaluate the combination in patients with SMARCA4-mutated cancers.

In part 2 of this video interview, Kristy Birchard, product owner, patient engagement, YPrime discusses the work she is currently doing within patient centricity and how to effectively reach patient communities.

Data emerged from the IDE397 Phase II monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients.

In part 1 of this video interview, Kristy Birchard, product owner, patient engagement, YPrime highlights the importance of patient centricity in trial design.

Study will evaluate the potential therapy in combination with checkpoint inhibitor in patients with malignant solid tumors.

Phase I dose escalation study expected to begin in the second half of 2024; initial data expected in the first half of 2025.

Preliminary results from study of small interfering RNA drug candidate, STP707, indicated the average days for stable disease in patients was 92.

Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit highlight the potential impact FDA's Diversity Action Plan guidance will have on industry.

Preliminary Phase II trial data showed tobevibart and elebsiran combination achieved high rates of virologic response.

Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit share their initial thoughts on the announcement of FDA's Diversity Action Plan guidance.

Results showed significant reduction in plasma levels of neurofilament light chain after one year of treatment, a key biomarker of nerve cell damage in relapsing MS.